Par Pharmaceutical

Jump to

Dr Reddy’s Suboxone launch: Why investors shrugged it off

Dr Reddy’s generic Suboxone launch is set to be a reality. A much-awaited event, a mounting threat from competitors may limit its benefits
Granules inks pact with Par Pharma for acid reflux drug

The company said it expects the US Food and Drug Administration's approvals by July this year. Par Pharmaceutical's, a subsidiary of Endo International plc, omeprazole and sodium bicarbonate is the generic version of Merck/MSD Consumer Care Inc's Zegerid.
Granules up 5% as US arm to market Par Pharma's anti-acid drug

"Granules USA, the wholly owned subsidiary of Granules India, entered into an agreement with Par Pharmaceutical Inc (a subsidiary of Endo International Plc) to market generic version of OTC omeprazole and sodium bicarbonate in North America," said Hyderabad-based pharma company.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Par Pharmaceutical

Dr Reddy’s Suboxone launch: Why investors shrugged it off

Granules inks pact with Par Pharma for acid reflux drug

Granules up 5% as US arm to market Par Pharma's anti-acid drug